Image
Getting on Track in Atopic Dermatitis An Interactive Educational Journey

Melinda Gooderham, MSc, MD, FRCPC

 

This activity is jointly provided by Global Education Group and Integritas Communications. 

 

This educational activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Faculty

Melinda Gooderham, MSc, MD, FRCPC
Medical Director of the SKiN Centre for Dermatology
Assistant Professor of Medicine
Queens University
Ontario, Canada

Program Description

The burden of Atopic Dermatitis (AD) is great, affecting patients and their families. A wide range of treatment options are available for moderate-to-severe disease, in the US and worldwide. New therapies are well tolerated and recently approved for children, teens, and adults. This Education StationTM is a 3-activity series created to help train clinicians in the long-haul endurance that is AD treatment and management. It is designed to allow you to flex your clinical management muscles as you progress through multiple exercises, building your atopic dermatitis knowledge and skills.

Target Audience

The educational design of this activity addresses the needs of an international audience of dermatologists, allergists, and other clinicians involved in the ongoing management of patients with moderate-to-severe atopic dermatitis.

Learning Objectives

After completing this activity, participants will be better prepared to:

  1. Describe atopic dermatitis pathophysiology with a focus on relationships with common comorbidities and targeted treatment options
  2. Assess patients with atopic dermatitis to characterize disease severity, biopsychosocial burdens, comorbidities, and treatment responses
  3. Discuss the clinical profiles and trial data for current and emerging targeted treatment options for moderate-to-severe atopic dermatitis
  4. Individualize treatment regimens for adult and pediatric patients with moderate-to-severe atopic dermatitis to reflect biopsychosocial burdens, comorbidities, and shared decision making

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.75 contact hour(s) (which includes 0.4 hour(s) of pharmacology).

EACCME

The UEMS-EACCME® and the AMA have recognized each other’s CME credits since 2000. In 2002 the UEMS-EACCME® and the AMA signed an agreement of mutual recognition of CME credits between Europe and the USA whereby European physicians attending an event in the USA have their credits recognized in Europe and American physicians attending an event in Europe have their credits recognized in the USA.

Royal College of Physicians and Surgeons of Canada

Activities held outside of Canada developed by a university, academy, specialty society, or other physician organization can be recorded as accredited group learning activities under Section 1 of the Royal College of Physician and Surgeons of Canada’s Maintenance of Certification (MOC) Program.

Japan Accreditation Council for Medical Education Credit

Activities certified by ACCME-accredited organizations may also allow Japanese learners to meet the criteria for Japan Accreditation Council for Medical Education credit.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation.

Disclosure of Conflicts of Interest

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global Education Group are required to disclose all financial relationships with any ineligible company within the past 24 months to Global Education Group. All financial relationships reported are identified as relevant and mitigated by Global Education Group in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global Education Group to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Melinda Gooderham, MSc, MD, FRCPC Consultant/Independent Contractor: AbbVie, Actelion, Akros, Amgen, Arena Pharm, Asana, Bausch, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen, Kyowa Kirin, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharmaceutical Industries, UCB; Grant/Research Support: AbbVie, Akros, Amgen, Arena Pharm, Arcutis, Bausch, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Janssen, Kyowa, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Sun Pharmaceutical Industries, Takeda, UCB; Honoraria: AbbVie, Actelion, Akros, Amgen, Arcutis, Arena Pharma, Asana, Bausch, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Sun Pharmaceutical Industries, Takeda, UCB; Speakers Bureau: AbbVie, Actelion, Amgen, Bausch, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Glenmark, Janssen, Leo Pharma, Merck, Novartis, Pfizer, Sanofi, Sun Pharmaceuticals, Takeda, UCB.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Stacey Ullman, MHS: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Term of Offering

This activity was released on February 4, 2022, and is valid for one year. Requests for credit must be made no later than February 4, 2023. 

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Education Group Contact Information

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 0.75

credit type CME/CE

release 02/04/2022

expiration 02/04/2023